Suppr超能文献

Sirt1 激活通过 Nrf2/ARE 通路预防大鼠抗 Thy 1.1 系膜增生性肾小球肾炎。

Sirt1 activation prevents anti-Thy 1.1 mesangial proliferative glomerulonephritis in the rat through the Nrf2/ARE pathway.

机构信息

Drug Clinical Trial Institution, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510060, China.

Department of Pharmacy, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.

出版信息

Eur J Pharmacol. 2018 Aug 5;832:138-144. doi: 10.1016/j.ejphar.2018.05.017. Epub 2018 May 18.

Abstract

Mesangial proliferative glomerulonephritis (MsPGN) is characterized by glomerular mesangial cells proliferation and extracellular matrix deposition in mesangial area, which develop into glomerulosclerosis. Both silent information regulator 2-related protein 1 (Sirt1) and nuclear factor erythroid 2-related factor 2/anti-oxidant response element (Nrf2/ARE) pathway had remarkable renoprotective effects. However, whether Sirt1 and Nrf2/ARE pathway can regulate the pathological process of MsPGN remains unknown. Here, we found that Sirt1 activation by SRT1720 decreased mesangial hypercellularity and mesangial matrix areas, reduced renal Col4 and α-SMA expressions, lowered 24 h proteinuria, and eventually reduced FN and TGF-β1 expressions in rats received anti-Thy 1.1 IgG. Further study showed that SRT1720 markedly enhanced the activity of Nrf2/ARE pathway including promoting the nuclear content and ARE-binding ability of Nrf2, elevating the protein levels of HO-1 and SOD1, two target genes of Nrf2, which eventually increased total SOD activity and decreased malondialdehyde level in the kidney tissues of experimental anti-Thy 1.1 MsPGN rats. Taken together, Sirt1 prevented the pathological process of experimental anti-Thy 1.1 MsPGN through promoting the activation of Nrf2/ARE pathway, which warrants further elucidation. Sirt1 might be a potential therapeutic target for treating MsPGN.

摘要

系膜增生性肾小球肾炎(MsPGN)的特征是肾小球系膜细胞增生和细胞外基质在系膜区沉积,进而发展为肾小球硬化。沉默信息调节因子 2 相关蛋白 1(Sirt1)和核因子红细胞 2 相关因子 2/抗氧化反应元件(Nrf2/ARE)通路均具有显著的肾脏保护作用。然而,Sirt1 和 Nrf2/ARE 通路是否能调节 MsPGN 的病理过程尚不清楚。在这里,我们发现 Sirt1 的激活剂 SRT1720 可减少系膜细胞增生和系膜基质面积,降低肾脏 Col4 和 α-SMA 的表达,降低抗-Thy 1.1 IgG 诱导的大鼠 24 小时蛋白尿,并最终降低 FN 和 TGF-β1 的表达。进一步的研究表明,SRT1720 显著增强了 Nrf2/ARE 通路的活性,包括促进 Nrf2 的核内容物和 ARE 结合能力,提高 Nrf2 的两个靶基因 HO-1 和 SOD1 的蛋白水平,最终增加总 SOD 活性并降低肾脏组织中丙二醛的水平在实验性抗-Thy 1.1 MsPGN 大鼠中。总之,Sirt1 通过促进 Nrf2/ARE 通路的激活来防止实验性抗-Thy 1.1 MsPGN 的病理过程,这值得进一步研究。Sirt1 可能是治疗 MsPGN 的潜在治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验